(Q37891987)

24 August 2017

1 reference

title

Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010. (English)

1 reference

24 August 2017

Samir Messaoudi

1

1 reference

24 August 2017

Jean-François Peyrat

series ordinal

2

1 reference

24 August 2017

Jean-Daniel Brion

series ordinal

3

1 reference

24 August 2017

Mouad Alami

series ordinal

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

21 June 2011

1 reference

Expert Opinion on Therapeutic Patents

24 August 2017

published in

1 reference

24 August 2017

volume

21

1 reference

24 August 2017

issue

10

1 reference

24 August 2017

page(s)

1501-1542

1 reference

Altered states: selectively drugging the Hsp90 cancer chaperone

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Hsp90: the vulnerable chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Inhibition of Hsp90: a new strategy for inhibiting protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Targeting multiple signal transduction pathways through inhibition of Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Hsp90 inhibitors as novel cancer chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Modulation of Akt kinase activity by binding to Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The glucocorticoid responses are shaped by molecular chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Chaperoning steroid hormone action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Stable association of hsp90 and p23, but Not hsp70, with active human telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Therapeutic and diagnostic implications of Hsp90 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

From the bench to the bedside: emerging new treatments in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Heat shock protein 90: the cancer chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Tosylcyclonovobiocic acids promote cleavage of the hsp90-associated cochaperone p23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Development and application of Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Emerging Hsp90 inhibitors: from discovery to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Using natural product inhibitors to validate Hsp90 as a molecular target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Inhibitors of the HSP90 molecular chaperone: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Targeting chaperones in transformed systems--a focus on Hsp90 and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Structure-based and in silico design of Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

ATPase inhibitors of heat-shock protein 90, second season

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Mechanistic studies on Hsp90 inhibition by ansamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Molecular characterization of macbecin as an Hsp90 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The purines: potent and versatile small molecule inhibitors and modulators of key biological targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Discovery and development of purine-scaffold Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Synthesis of Hsp90 inhibitor dimers as potential antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Orally active purine-based inhibitors of the heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Fragment-based identification of Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Discovery and development of pyrazole-scaffold Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Potent triazolothione inhibitor of heat-shock protein-90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Withaferin A targets heat shock protein 90 in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Development of Radicicol Analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Radanamycin, a macrocyclic chimera of radicicol and geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Heat shock protein 90: inhibitors in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The Hsp90 molecular chaperone: an open and shut case for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Rational design of shepherdin, a novel anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

Total Synthesis as a Resource in the Discovery of Potentially Valuable Antitumor Agents: Cycloproparadicicol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.594041

10.1517/13543776.2011.594041

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference